This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carroll, R Articles by Derse, D Search for Related Content PubMed PubMed Citation Articles by Carroll, R Articles by Derse, D

Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators.

Laboratory of Viral Carcinogenesis, National Cancer Institute, Frederick Cancer Research and Development Center, Maryland 21702-1201.

ABSTRACT

We examined the mechanism of Tat-mediated trans activation through competition experiments employing Tat proteins of human immunodeficiency virus type 1 (HIV-1) and equine infectious anemia virus (EIAV). EIAV Tat, as well as chimeric EIAV/HIV-1 Tat proteins, inhibited HIV-1 Tat-mediated trans activation in a cell-type-dependent fashion. Furthermore, these proteins inhibited trans activation by Tat-bacteriophage R17 coat protein chimeras. Inhibition resulted from competition between activation domains of effectors and competitors for a limiting cellular cofactor. The context in which competitor activation domains were expressed contributed to the extent of inhibition. In transfected cells, EIAV Tat and all chimeric competitors were located primarily in the cytoplasm, whereas HIV-1 Tat was primarily located in the nucleus. These data are consistent with a model for trans activation in which the activation domain of Tat associates with and conveys a cellular factor to the transcription complex via the trans-acting-responsive element (TAR).

This article has been cited by other articles:

• Kim, B. O., Liu, Y., Zhou, B. Y., He, J. J. (2004). Induction of C Chemokine XCL1 (Lymphotactin/Single C Motif-1{alpha}/Activation-Induced, T Cell-Derived and Chemokine-Related Cytokine) Expression by HIV-1 Tat Protein. J. Immunol. 172: 1888-1895 [Abstract] [Full Text]  
• Lund, L. H., Wahren, B., Garcia-Blanco, M. A. (2003). A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo. J. Gen. Virol. 84: 603-606 [Abstract] [Full Text]  
• Lecellier, C.-H., Neves, M., Giron, M.-L., Tobaly-Tapiero, J., Saib, A. (2002). Further Characterization of Equine Foamy Virus Reveals Unusual Features among the Foamy Viruses. J. Virol. 76: 7220-7227 [Abstract] [Full Text]  
• Marcello, A., Cinelli, R. A. G., Ferrari, A., Signorelli, A., Tyagi, M., Pellegrini, V., Beltram, F., Giacca, M. (2001). Visualization of in Vivo Direct Interaction between HIV-1 TAT and Human Cyclin T1 in Specific Subcellular Compartments by Fluorescence Resonance Energy Transfer. J. Biol. Chem. 276: 39220-39225 [Abstract] [Full Text]  
• Price, D. H. (2000). P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II. Mol. Cell. Biol. 20: 2629-2634 [Full Text]  
• Taube, R., Fujinaga, K., Irwin, D., Wimmer, J., Geyer, M., Peterlin, B. M. (2000). Interactions between Equine Cyclin T1, Tat, and TAR Are Disrupted by a Leucine-to-Valine Substitution Found in Human Cyclin T1. J. Virol. 74: 892-898 [Abstract] [Full Text]  
• Ramanathan, Y., Reza, S. M., Young, T. M., Mathews, M. B., Pe'ery, T. (1999). Human and Rodent Transcription Elongation Factor P-TEFb: Interactions with Human Immunodeficiency Virus Type 1 Tat and Carboxy-Terminal Domain Substrate. J. Virol. 73: 5448-5458 [Abstract] [Full Text]  
• Bieniasz, P. D., Grdina, T. A., Bogerd, H. P., Cullen, B. R. (1999). Highly Divergent Lentiviral Tat Proteins Activate Viral Gene Expression by a Common Mechanism. Mol. Cell. Biol. 19: 4592-4599 [Abstract] [Full Text]  
• Fujinaga, K., Taube, R., Wimmer, J., Cujec, T. P., Peterlin, B. M. (1999). Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc. Natl. Acad. Sci. USA 96: 1285-1290 [Abstract] [Full Text]  
• Fujinaga, K., Cujec, T. P., Peng, J., Garriga, J., Price, D. H., Grana, X., Peterlin, B. M. (1998). The Ability of Positive Transcription Elongation Factor b To Transactivate Human Immunodeficiency Virus Transcription Depends on a Functional Kinase Domain, Cyclin T1, and Tat. J. Virol. 72: 7154-7159 [Abstract] [Full Text]  
• Gold, M. O., Yang, X., Herrmann, C. H., Rice, A. P. (1998). PITALRE, the Catalytic Subunit of TAK, Is Required for Human Immunodeficiency Virus Tat Transactivation In Vivo. J. Virol. 72: 4448-4453 [Abstract] [Full Text]  
• Zhu, Y., Pe'ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B., Price, D. H. (1997). Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev. 11: 2622-2632 [Abstract] [Full Text]  
• Cujec, T. P., Okamoto, H., Fujinaga, K., Meyer, J., Chamberlin, H., Morgan, D. O., Peterlin, B. M. (1997). The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11: 2645-2657 [Abstract] [Full Text]  
• Chun, R. F., Jeang, K.-T. (1996). Requirements for RNA Polymerase II Carboxyl-terminal Domain for Activated Transcription of Human Retroviruses Human T-Cell Lymphotropic Virus I and HIV-1. J. Biol. Chem. 271: 27888-27894 [Abstract] [Full Text]  
• Willbold, D, Rosin-Arbesfeld, R, Sticht, H, Frank, R, Rosch, P (1994). Structure of the equine infectious anemia virus Tat protein. Science 264: 1584-1587 [Abstract]  
• Tiley, L S, Madore, S J, Malim, M H, Cullen, B R (1992). The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.. Genes Dev. 6: 2077-2087 [Abstract]